[HTML][HTML] Using pneumococcal carriage studies to monitor vaccine impact in low-and middle-income countries
Pneumococcal disease is a leading cause of childhood mortality, globally. The
pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide …
pneumococcal conjugate vaccine (PCV) has been introduced to many countries worldwide …
[HTML][HTML] Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal …
Pneumococcal carriage is a prerequisite for disease, and underpins herd protection
provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of …
provided by pneumococcal conjugate vaccines (PCVs). There are few data on the impact of …
Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumococcal carriage in Fiji: results from four annual cross-sectional carriage surveys
Background The indirect effects of pneumococcal conjugate vaccines (PCVs) are mediated
through reductions in carriage of vaccine serotypes. Data on PCVs in Asia and the Pacific …
through reductions in carriage of vaccine serotypes. Data on PCVs in Asia and the Pacific …
Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada
M Wilson, M Wasserman, T Jadavi, M Postma… - Infectious diseases and …, 2018 - Springer
Abstract Introduction Pneumococcal conjugate vaccines (PCVs) have been available in
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization …
Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype …
P Izurieta, P Bahety, R Adegbola, C Clarke… - Expert review of …, 2018 - Taylor & Francis
Introduction: Pneumococcal conjugate vaccine (PCV) impact studies have reported
substantial reductions in the incidence of invasive pneumococcal disease (IPD) after …
substantial reductions in the incidence of invasive pneumococcal disease (IPD) after …
The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries
The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While
Sustaining Herd Immunity in High-Income Countries | PLOS Medicine Skip to main content …
Sustaining Herd Immunity in High-Income Countries | PLOS Medicine Skip to main content …
The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
AL Adamu, J Ojal, IA Abubakar, KA Odeyemi… - Nature …, 2023 - nature.com
Pneumococcal conjugate vaccines (PCVs) protect against invasive pneumococcal disease
(IPD) among vaccinees. However, at population level, this protection is driven by indirect …
(IPD) among vaccinees. However, at population level, this protection is driven by indirect …
Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine
M Wasserman, HL Sings, D Jones, S Pugh… - Expert review of …, 2018 - Taylor & Francis
ABSTRACT Introduction: Pneumococcal conjugate vaccines (PCVs) have provided a
significant clinical and economic impact globally. The majority of countries which have …
significant clinical and economic impact globally. The majority of countries which have …
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
K Shen, M Wasserman, D Liu, YH Yang, J Yang… - PLoS …, 2018 - journals.plos.org
Background The burden of pneumococcal disease in China is high, and a 13-valent
pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is …
pneumococcal conjugate vaccine (PCV13) recently received regulatory approval and is …
Cost effectiveness of child pneumococcal conjugate vaccination in GAVI-eligible countries
A Tasslimi, MM Nakamura, O Levine, MD Knoll… - International …, 2011 - Elsevier
Policy-makers increasingly rely on cost-effectiveness analysis, in addition to clinical
effectiveness, when considering the introduction of new childhood vaccines. A previous …
effectiveness, when considering the introduction of new childhood vaccines. A previous …